Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
AstraZeneca
Dow
Boehringer Ingelheim
Express Scripts

Last Updated: August 10, 2022

Investigational Drug Information for PF-06651600


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug PF-06651600?

PF-06651600 is an investigational drug.

There have been 30 clinical trials for PF-06651600. The most recent clinical trial was a Phase 3 trial, which was initiated on December 3rd 2018.

The most common disease conditions in clinical trials are Alopecia Areata, Alopecia, and Arthritis, Rheumatoid. The leading clinical trial sponsors are Pfizer and [disabled in preview].

There is one US patent protecting this investigational drug and fifty-one international patents.

Recent Clinical Trials for PF-06651600
TitleSponsorPhase
Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of TolbutamidePfizerPhase 1
A Target Occupancy Study With Ritlecitinib.PfizerPhase 1
Estimation of the Effect of Multiple Dose Ritlecitinib (PF-06651600) on the Pharmacokinetics of a Single Dose of Caffeine in Healthy ParticipantsPfizerPhase 1

See all PF-06651600 clinical trials

Clinical Trial Summary for PF-06651600

Top disease conditions for PF-06651600
Top clinical trial sponsors for PF-06651600

See all PF-06651600 clinical trials

International Patents for PF-06651600

Drugname Country Document Number Estimated Expiration Related US Patent
PF-06651600 Argentina AR099363 2033-12-05 See Plans and Pricing
PF-06651600 Australia AU2014358792 2033-12-05 See Plans and Pricing
PF-06651600 Brazil BR112016012262 2033-12-05 See Plans and Pricing
PF-06651600 Canada CA2932425 2033-12-05 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
AstraZeneca
Dow
Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.